10-KPeriod: FY2019

IDEXX LABORATORIES INC /DE Annual Report, Year Ended Dec 31, 2019

Filed February 14, 2020For Securities:IDXX

Summary

IDEXX Laboratories, Inc. (IDXX) reported strong performance in its 2019 fiscal year, characterized by robust revenue growth driven primarily by its Companion Animal Group (CAG) segment. The company demonstrated a consistent upward trend in both reported and organic revenue, with a notable increase in gross profit margin attributed to favorable product mix, volume leverage, and price increases in recurring revenue streams. Investments in research and development remain a priority, indicating a focus on continued innovation and market leadership. The company's financial health appears solid, with healthy operating income and a strong balance sheet, although it manages a significant amount of long-term debt. IDEXX also actively engages in share repurchases, returning value to shareholders and offsetting the dilutive effects of equity-based compensation. Looking ahead, IDEXX is focused on expanding its installed base of diagnostic instruments, driving recurring revenue from consumables and services, and leveraging its integrated technology platforms to enhance veterinary care and practice efficiency. The company remains optimistic about its growth prospects across its key segments.

Financial Highlights

54 data points
Beta

Revenue

$2.41B

56.7% Gross Margin

Net Income

$427.79M

17.8% Net Margin

EPS (Diluted)

$4.89

Total Assets

$1.83B

Cash & Equivalents

$90.33M

Free Cash Flow

$304.19M

Financial Statements
Beta
Revenue$2.41B
Cost of Revenue$1.04B
Gross Profit$1.37B
R&D Expenses$133.19M
Operating Income$552.85M
Interest Expense$31.05M
Net Income$427.79M
EPS (Basic)$4.97
EPS (Diluted)$4.89
Shares Outstanding (Basic)86.11M
Shares Outstanding (Diluted)87.54M

Key Highlights

  • 1Strong Revenue Growth: IDEXX reported a 8.8% increase in total revenue to $2.41 billion for the year ended December 31, 2019, with organic revenue growth of 10.3%.
  • 2Companion Animal Group (CAG) Dominance: The CAG segment remains the primary revenue driver, with a 9.5% increase in net revenue, largely fueled by recurring diagnostic revenues from consumables and reference laboratory services.
  • 3Improved Profitability: Gross profit increased by 10.0% to $1.37 billion, with a gross profit margin of 56.7%, up from 56.1% in the prior year, driven by favorable product mix and operational efficiencies.
  • 4Consistent Investment in R&D: Research and development expenses increased by 13.0% to $133.2 million, underscoring the company's commitment to innovation.
  • 5Healthy Operating Income: Income from operations grew by 12.5% to $552.8 million, reflecting efficient cost management and revenue growth.
  • 6Shareholder Returns: The company repurchased approximately 1.2 million shares of common stock for $303.8 million during 2019, indicating a commitment to returning capital to shareholders.
  • 7Strong Cash Flow from Operations: Net cash provided by operating activities increased by 14.8% to $459.2 million, demonstrating strong operational performance.

Frequently Asked Questions

IDEXX Laboratories primarily develops, manufactures, and distributes products and services for the companion animal veterinary market (Companion Animal Group - CAG), as well as for livestock, poultry, and dairy (LPD), and water testing (Water). The CAG segment is the largest and most significant, encompassing diagnostic products, services, and practice management solutions. The company also has an 'Other' segment which includes its human point-of-care medical diagnostics business (OPTI Medical).

Revenue growth in 2019 was primarily driven by strong volume gains in CAG Diagnostics recurring revenue, supported by differentiated diagnostic technologies and an expanded commercial organization. This included growth in IDEXX VetLab consumables, reference laboratory diagnostic and consulting services, and rapid assay products. The Water business also contributed positively due to higher sales volumes of Colilert test products. The LPD business saw growth from African swine fever testing and increased poultry diagnostics, partially offsetting lower swine testing volumes in China.

IDEXX funds its operations, capital expenditures, and growth initiatives through cash on hand, operational cash flow, and its revolving credit facility. As of December 31, 2019, the company had $90.3 million in cash and cash equivalents and substantial borrowing availability under its credit facility. The company maintains a healthy debt-to-adjusted EBITDA ratio and actively manages its capital structure, including share repurchases.

Key risks include intense competition in the companion animal healthcare industry, potential disruptions in its supply chain due to sole or single-source suppliers, cybersecurity threats impacting IT systems, risks associated with international operations (including currency fluctuations and regulatory compliance), changes in testing patterns, and potential negative impacts from economic downturns on customer spending. The company also highlights risks related to its limited experience in the human point-of-care market.